Compare AbbVie Inc (ABBV) vs ServiceNow Inc (NOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ServiceNow Inc — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while ServiceNow Inc trades at $107.1 (market cap $114.20B). The key difference: AbbVie Inc is far larger — about 3.9× ServiceNow Inc's market cap, and AbbVie Inc pays a 2.72% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| ABBV | NOW | |
|---|---|---|
Market Cap | $449.91B | $114.20B |
Sector | Health | Technology |
52-Week High | $261.07 | $204.60 |
52-Week Low | $184.85 | $83.00 |
Enterprise Value | $513.38B | $111.45B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ServiceNow (NOW) trades at $107.93, up 1.51% today, with a bullish technical outlook supported by positive moving averages. The company reported strong revenue growth to $13.28 billion in 2025 and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth potential and conference presentations, while analyst consensus remains strongly bullish with an 85.51% buy rating.
The outlook for NOW is positive due to robust fundamentals and AI adoption, but high valuation multiples (P/E 64.24) pose a risk if growth slows. Upside to the $136.43 price target offers potential, yet investors face volatility from competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
